Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16O6 |
Molecular Weight | 316.3053 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=C(OCCCOC2=CC=C(C=C2)C(O)=O)C=C1
InChI
InChIKey=VBISQLWPGDULSX-UHFFFAOYSA-N
InChI=1S/C17H16O6/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21/h2-9H,1,10-11H2,(H,18,19)(H,20,21)
DescriptionCurator's Comment: description was created based on several sources, including:
http://arborpharma.com/docs/201241r1-gliadel-pi.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7948590 | https://www.ncbi.nlm.nih.gov/pubmed/1350734
Curator's Comment: description was created based on several sources, including:
http://arborpharma.com/docs/201241r1-gliadel-pi.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7948590 | https://www.ncbi.nlm.nih.gov/pubmed/1350734
BENZOIC ACID, 4,4'-(1,3-PROPANEDIYLBIS(OXY))BIS- (CPP-BIS) is a building block for polyanhydrides, which is a class of bioerodible polymer containing drug delivery applications. The polyanhydride copolymer system which currently enjoys the most widespread interest in its medical applications employs the monomers sebacic acid (SA) and CPP-BIS (Polifeprosan). Polifeprosan is a biodegradable copolymer used to control the release of carmustine in GLIADEL Wafer. GLIADEL Wafer is an implant for intracranial use, containing carmustine, a nitrosourea alkylating agent. GLIADEL Wafer is indicated in newly-diagnosed high-grade malignant glioma patients and in recurrent glioblastoma multiforme. Most common adverse reactions of GLIADEL Wafer are cerebral edema, asthenia, nausea, vomiting, constipation, wound healing abnormalities and depression.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3880353
Curator's Comment: http://www-heparin.rpi.edu/main/files/papers/14.pdf | https://www.ncbi.nlm.nih.gov/pubmed/1350734
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Gliadel Wafer Approved UseGLIADEL® Wafer is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. GLIADEL® Wafer is indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Launch Date2003 |
|||
Primary | Gliadel Wafer Approved UseGLIADEL® Wafer is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. GLIADEL® Wafer is indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Launch Date2003 |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and characterization of polyanhydride for local BCNU delivery carriers. | 2005 |
|
Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. | 2007 Oct |
|
catena-Poly[[aqua-(1,10-phenanthroline)cobalt(II)]-μ-4,4'-(propane-1,3-diyldi-oxy)dibenzoato]. | 2009 Sep 5 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1XMW35DTHB
Created by
admin on Fri Dec 15 17:33:44 GMT 2023 , Edited by admin on Fri Dec 15 17:33:44 GMT 2023
|
PRIMARY | |||
|
3753-81-9
Created by
admin on Fri Dec 15 17:33:44 GMT 2023 , Edited by admin on Fri Dec 15 17:33:44 GMT 2023
|
PRIMARY | |||
|
68610
Created by
admin on Fri Dec 15 17:33:44 GMT 2023 , Edited by admin on Fri Dec 15 17:33:44 GMT 2023
|
PRIMARY | |||
|
DTXSID8046585
Created by
admin on Fri Dec 15 17:33:44 GMT 2023 , Edited by admin on Fri Dec 15 17:33:44 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD